Insider Cluster (3 insiders) ·Filed Aug 6, 2026

ARQT

Arcutis Biotherapeutics, Inc.
NEUTRAL
Impact 2/10
Horizonimmediate Processed1mo ago
Insider cluster: 2 insiders, $171K total
Actionable Insight • Neutral

This cluster is too small to warrant a trading response. Monitor for any larger insider sales or C-suite participation in future filings. The 60% win rate on prior ARQT reports suggests the stock has been trending positively, but this filing provides no new information.

DirectionNeutral
Confidencehigh
Horizonimmediate
Latest settled — T+20d ⚠ clustered
ARQT ▼ -10.48% at T+20d
NEUTRAL call ✗ call lost -10.48% · α vs SPY -11.08% · entry $26.43 → $23.66
Next anchor: T+60d in 27d
Latest observation: T+37 -6.65% FF3 residual α
Entry anchored
Aug 5, 07:59 PM ET
via 1-min bar
T+1d
-4.31%
call -4.31% · α -4.92%
$25.29
settled 8w ago
T+5d
-2.27%
call -2.27% · α -3.48%
$25.83
settled 7w ago
T+20d
-10.48%
call -10.48% · α -11.08%
$23.66
settled 4w ago
T+60d
—
call — · α —
—
in 27d

Price Chart

Loading chart...

Executive Summary

Three Arcutis insiders (Watanabe, Matsuda, Burnett) sold a total of $171K in open-market sales on August 3, 2026, at ~$26.12/share. The dollar value is trivial relative to the $3.3B market cap (~0.005%), and the cluster is small with no C-suite participation. This is routine liquidity-driven selling, not a bearish signal.

Key Financial Metrics

Direction
selling
Total Value
$171.0K
Insiders
3

Key Facts

  • Three insiders sold a total of 6,560 shares for $171K on August 3, 2026
  • Sales were all open-market (code S) at ~$26.12/share
  • Total value is ~0.005% of Arcutis's $3.3B market cap — immaterial
  • No C-suite executives (CEO, CFO, COO) participated; all filers are 'See Remarks'
  • Cluster is small and isolated; no pattern suggesting 10b5-1 or vesting-driven sales

Financial Impact

Total insider sales of $171K represent ~0.005% of $3.3B market cap — economically trivial

insider ownership

Risk Factors

  • Insider sales could accelerate if stock continues to rise, but current level is routine
  • No indication of negative corporate events from this cluster

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
86% bullish (14 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-ARQT-1785981669787
17 reports for ARQT
Performance horizon
67% Hit rate 2 of 3 directional calls best @ T+60▲ +14.74%Mar 2, 2026
Filters
Rows
Reports for ARQT — sortable, filterable
TypeNow
Aug 24, 2026
5w ago
Insider Cluster
NEUTRAL ★ 2/10
$24.86 $26.38▲ +6.11%▲ +5.87%$25.16 (+1.21%)
Aug 21, 2026
6w ago
Insider Cluster
NEUTRAL ★ 2/10
$25.08 $25.96▲ +3.51%▲ +4.04%$25.16 (+0.32%)
Aug 19, 2026
6w ago
Insider Cluster
NEUTRAL ★ 2/10
$25.35 $25.38▲ +0.12%▲ +0.12%$25.16 (−0.75%)
Aug 11, 2026
7w ago
144
NEUTRAL ★ 3/10
$26.28 $23.38▼ −11.04%▼ −9.14%$25.16 (−4.26%)
Aug 6, 2026
8w ago
Insider Cluster
NEUTRAL ★ 2/10
$26.43 $23.66▼ −10.48%▼ −11.08%$25.16 (−4.81%)
Aug 5, 2026
8w ago
Press Release
BULLISH ★ 7/10
$26.43 $23.66▼ −10.48%▼ −11.08%$25.16 (−4.81%)
Aug 3, 2026
8w ago
144
NEUTRAL ★ 2/10
$26.03 $23.75▼ −8.76%▼ −7.52%$25.16 (−3.34%)
Jun 29, 2026
13w ago
Press Release
BULLISH ★ 7/10
$26.22 $27.84▲ +6.18%▲ +7.21%$25.16 (−4.04%)
Jun 18, 2026
15w ago
Insider Cluster
NEUTRAL ★ 2/10
$26.21 $27.74▲ +5.84%▲ +5.30%$25.16 (−4.01%)
Jun 9, 2026
16w ago
8-K
NEUTRAL ★ 2/10
$23.23 $28.78▲ +23.89%▲ +20.27%$25.16 (+8.31%)
Showing 10 of 17

US Market Status

Market Closed — Opens Mon (64h 37m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access
Report published Aug 6, 2026